Skip to main content

Table 2 Clinical and laboratory data at baseline and at the end of the study of MACE and non-MACE subgroups (MACE- major adverse cardiovascular events)

From: Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease

 

Groups

P value

MACE

(N = 75)

Non-MACE

(N = 124)

Baseline

12 months

Baseline

12 months

Age (y)

81 ± 15

–

76 ± 12

–

0.432

Males, n (%)

60 (80)

 

101 (81.4)

 

0.951

Smoking, n (%)

32 (42.7)

18 (24)

18 (14.5)#

9 (7.5)

 < 0.001

Hypertension, n (%)

58 (77.3)

–

90 (72.6)

–

0.383

Dyslipidemia, n (%)

73 (97.3)

–

119 (96)

–

0.909

Statins, n (%)

73 (97.3)

74 (98.7)

118 (95.2)

121 (97.6)

0.943

ABI

0.49 (0.09)

–

0.54 (0.09)

–

0.799

Diabetes, n (%)

34 (45.3)

–

45 (36.3)

–

0.206

BMI (kg/m2)

27.98 ± 3.72

27.56 ± 3.55

28.21 ± 3.9

28 ± 3.7

0.922

SBP (mmHg)

144 ± 24

140 ± 25

135 ± 24#

134 ± 28

0.108

DBP (mmHg)

85 ± 8

84 ± 7

85 ± 9

85 ± 10

0.998

TChol (mg/dl)

176 ± 49

167 ± 46

165 ± 41

159 ± 46

0.967

HDL-C (mg/dl)

38 ± 8

39 ± 7

41 ± 11

42 ± 9

0.781

LDL-C (mg/dl)

130 ± 43

104 ± 37*

102 ± 35#

92 ± 22*

0.043

TG (mg/dl)

132 ± 61

120 ± 61

109 ± 42

101 ± 42

0.070

Creatinine (mg/dl)

1.42 ± 0.55

1.35 ± 0.52

1.27 ± 0.47

1.20 ± 0.37

0.980

GFR (mL/min/1.73 m2)

47 ± 12

50 ± 12

55 ± 19

58 ± 19

0.926

FPG (mg/dl)

155 ± 45

135 ± 45*

146 ± 41

128 ± 28

0.900

HbA1c (%)a

7.9 ± 1.4

7.3 ± 1.1

7.3 ± 1.3

6.9 ± 0.9

0.131

hsCRP (mg/L)

8.05 ± 2.67

4.79 ± 1.27

5.55 ± 2.12#

2.98 ± 1.05

 < 0.001

OPN (ng/ml)

96.45 ± 40.12

78.1 ± 38.29

73.05 ± 29.88#

51.66 ± 18.77*

 < 0.001

OPG (pmol/L)

13.29 ± 3.23

10.86 ± 3*

9.04 ± 3.56#

6.12 ± 2.34*

 < 0.001

  1. Data are expressed as means ± SD
  2. n number of patients; BMI body-mass index; SBP systolic blood pressure DBP diastolic blood pressure; TChol total cholesterol; TG triglycerides; FPG fasting plasma glucose; hsCRP high-sensitivity C-Reactive Protein; OPN osteopontin; OPG osteoprotegerin
  3. P value of changes of variables between groups
  4. *p < 0.05 of changes of variables within groups
  5. #p < 0.05 of differences of variables between groups at baseline
  6. aHbA1c was measured only in diabetic patients